

Axel Schlitt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4289945/publications.pdf>

Version: 2024-02-01

44
papers

1,707
citations

361413
20
h-index

276875
41
g-index

44
all docs

44
docs citations

44
times ranked

2750
citing authors

#	ARTICLE	IF	CITATIONS
1	CD14+CD16+ monocytes in coronary artery disease and their relationship to serum TNF- α levels. Thrombosis and Haemostasis, 2004, 92, 419-424.	3.4	276
2	Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. European Heart Journal, 2017, 38, 2671-2679.	2.2	243
3	Monocyte heterogeneity in obesity and subclinical atherosclerosis. European Heart Journal, 2010, 31, 369-376.	2.2	172
4	High Plasma Phospholipid Transfer Protein Levels as a Risk Factor for Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003, 23, 1857-1862.	2.4	120
5	Further evaluation of plasma sphingomyelin levels as a risk factor for coronary artery disease. Nutrition and Metabolism, 2006, 3, 5.	3.0	108
6	Cardiotoxicity and Oncological Treatments. Deutsches Arzteblatt International, 2014, 111, 161-8.	0.9	73
7	CHADS ₂ , CHA ₂ DS ₂ -VASc and HAS-BLED as predictors of outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention. Thrombosis Research, 2014, 133, 560-566.	1.7	58
8	Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro. Coronary Artery Disease, 2007, 18, 523-531.	0.7	53
9	Clopidogrel and aspirin in the prevention of thromboembolic complications after mechanical aortic valve replacement (CAPTA). Thrombosis Research, 2003, 109, 131-135.	1.7	49
10	Anti-inflammatory effects of phospholipid transfer protein (PLTP) deficiency in mice. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2005, 1733, 187-191.	2.4	49
11	PLTP activity is a risk factor for subsequent cardiovascular events in CAD patients under statin therapy: the AtheroGene Study. Journal of Lipid Research, 2009, 50, 723-729.	4.2	35
12	C-reactive protein levels and genetic variants of CRP as prognostic markers for combined cardiovascular endpoint (cardiovascular death, death from stroke, myocardial infarction, and) Tj ETQq0 0 0 rgBT /Overlock 108If 50 297		
13	Soluble form of receptor for advanced glycation end products and incidence of new cardiovascular events among patients with cardiovascular disease. Atherosclerosis, 2017, 266, 234-239.	0.8	31
14	Performance of Bleeding Risk-Prediction Scores in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2014, 113, 1995-2001.	1.6	26
15	Periodontal conditions and incidence of new cardiovascular events among patients with coronary vascular disease. Journal of Clinical Periodontology, 2016, 43, 918-925.	4.9	26
16	Prognostic value of lipoproteins and their relation to inflammatory markers among patients with coronary artery disease. International Journal of Cardiology, 2005, 102, 477-485.	1.7	25
17	Feasibility and safety of rehabilitation after venous thromboembolism. Vascular Health and Risk Management, 2015, 11, 397.	2.3	25
18	Serum sphingomyelin levels are related to the clearance of postprandial remnant-like particles. Journal of Lipid Research, 2005, 46, 196-200.	4.2	24

#	ARTICLE	IF	CITATIONS
19	Subgroups of monocytes predict cardiovascular events in patients with coronary heart disease. The PHAMOS trial (Prospective Halle Monocytes Study). Hellenic Journal of Cardiology, 2019, 60, 311-321.	1.0	24
20	Prognosis of patients with pulmonary embolism after rehabilitation. Vascular Health and Risk Management, 2018, Volume 14, 183-187.	2.3	23
21	Cardiac Rehabilitation in German Speaking Countries of Europe – Evidence-Based Guidelines from Germany, Austria and Switzerland LLKardReha-DACH – Part 1. Journal of Clinical Medicine, 2021, 10, 2192.	2.4	23
22	The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation. Catheterization and Cardiovascular Interventions, 2013, 82, E864-70.	1.7	19
23	Herpesvirus DNA (Epstein-Barr virus, herpes simplex virus, cytomegalovirus) in circulating monocytes of patients with coronary artery disease. Acta Cardiologica, 2005, 60, 605-610.	0.9	18
24	Fondaparinux and enoxaparin in comparison to unfractionated heparin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model. Thrombosis and Haemostasis, 2003, 90, 245-251.	3.4	17
25	Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: The AFCAS study. International Journal of Cardiology, 2015, 183, 105-110.	1.7	17
26	Periodontal pathogens and their role in cardiovascular outcome. Journal of Clinical Periodontology, 2020, 47, 173-181.	4.9	16
27	Impact of anaemia on clinical outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. BMJ Open, 2014, 4, e004700.	1.9	15
28	Argatroban and bivalirudin compared to unfractionated heparin in preventing thrombus formation on mechanical heart valves. Thrombosis and Haemostasis, 2009, 101, 1163-1169.	3.4	13
29	Rehabilitation in Patients With Coronary Heart Disease. Deutsches Arzteblatt International, 2015, 112, 527-34.	0.9	13
30	In-vitro comparison of fondaparinux, unfractionated heparin, and enoxaparin in preventing cardiac catheter-associated thrombus. Coronary Artery Disease, 2008, 19, 279-284.	0.7	12
31	Phospholipid Transfer Protein in Hemodialysis Patients. American Journal of Nephrology, 2007, 27, 138-143.	3.1	11
32	Comparison of fondaparinux, low molecular-weight heparin and unfractionated heparin in preventing thrombus formation on mechanical heart valves: results of an in-vitro study. Journal of Heart Valve Disease, 2006, 15, 809-14.	0.5	11
33	Bivalirudin use during percutaneous coronary intervention in patients on chronic warfarin therapy. Thrombosis Research, 2014, 133, 695-696.	1.7	8
34	Renal Impairment and Prognosis of Patients with Atrial Fibrillation Undergoing Coronary Intervention - The AFCAS Trial. PLoS ONE, 2015, 10, e0128492.	2.5	8
35	ANRIL polymorphisms (rs1333049 and rs3217992) in relation to plasma CRP levels among in-patients with CHD. Cytokine, 2020, 127, 154932.	3.2	8
36	Value of DAPT score to predict adverse outcome in patients with atrial fibrillation undergoing percutaneous coronary intervention: A post-hoc analysis from the AFCAS registry. International Journal of Cardiology, 2018, 253, 35-39.	1.7	7

#	ARTICLE	IF	CITATIONS
37	The interleukin 6 c.-174 CC genotype is a predictor for new cardiovascular events in patients with coronary heart disease within three years follow-up. Cytokine, 2016, 83, 136-138.	3.2	6
38	Serum Phospholipid Transfer Protein Activity After a High Fat Meal in Patients with Insulinâ€Treated Type 2 Diabetes. Lipids, 2010, 45, 129-135.	1.7	3
39	Interactive patient education via an audience response system in cardiac rehabilitation. SAGE Open Medicine, 2020, 8, 205031212094211.	1.8	3
40	Letter to the Editor regarding Dounousi E <i>et al</i> . Intact <sc>FGF</sc>23 and Î±â€Klotho during acute inflammation/sepsis in <sc>CKD</sc> patients. European Journal of Clinical Investigation, 2017, 47, 468-469.	3.4	2
41	Outcome of octogenarians with atrial fibrillation undergoing percutaneous coronary intervention: insights from the AFCAS registry. Clinical Cardiology, 2017, 40, 1264-1270.	1.8	2
42	Comparison between bicycle ergometric interval and continuous training in patients early after coronary artery bypass grafting: A prospective, randomized study. SAGE Open Medicine, 2021, 9, 205031212110382.	1.8	2
43	Data on IL-6 c.-174 G>C genotype and allele frequencies in patients with coronary heart disease in dependence of cardiovascular outcome. Data in Brief, 2016, 8, 1295-1299.	1.0	1
44	Polymorphism of CD14 Gene Is Associated with Adverse Outcome among Patients Suffering from Cardiovascular Disease. Mediators of Inflammation, 2021, 2021, 1-10.	3.0	1